Analysts await Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.1 EPS, up 0% or $0 from last year’s $-0.1 per share.

At the moment 7 analysts are watching Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), 0 rate it “Buy”, 2 “Outperform”, 5 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 6 analysts have a mean sales target of 9.75 million. For the quarter ending Sep-16, 6 analysts have a mean sales target of 13.83 million whilst for the year ending Dec-16, 7 analysts have a mean target of 45.57 million.

In terms of earnings per share, 6 analysts have a -0.10 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 6 analysts have a -0.09 EPS mean target and for the quarter ending Sep-16 there are 7 estimates of -0.39 EPS.

The biggest institutional shareholders in Arena Pharmaceuticals, Inc. include Wellington Management Company LLP which owns 25 million shares in the company valued at $47.56 million. Vanguard Group Inc is the second biggest holder with 17 million shares currently valued at 32.61 million whilst Fidelity Management and Research Company has 14 million shares valued at 26.84 million.

Total shares held by institutions as of the most recent company filings are 125,783,676 with a reported 5,690,522 bought and 21,360,307 sold. These holdings make up 51.81% of the company’s outstanding shares.

Currently insiders hold 2,771,180 shares in the business which makes up 1.14% of shares. The biggest holder currently is Jack Lief who owns 622,189 shares (0.26% of those outstanding), whilst Dr. Dominic P. Behan,PhD holds 508,000 (0.21% of shares outstanding) and Dr. Derek T. Chalmers,PhD holds 370,667 (0.15% of shares outstanding).

The stock decreased 0.95% or $0.02 during the last trading session, hitting $1.89. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has fallen 8.99% over the past 6 months and is downtrending.